Dopamine (DA) is a neurotransmitter used throughout phylogeny to modulate circuits controlling movement, attention, reward and cognition. Alterations in DA signaling in man have been implicated in Parkinson's Disease, Attention-Deficit Hyperactivity Disorder (ADHD), addiction and schizophrenia. DA signaling is tightly controlled by a presynaptic, DA transporter (DAT) that is a major target for addictive psychostimulants such as cocaine and amphetamine (AMPH), as well as agents used in the treatment of ADHD. Our recent identification of multiple, functional alleles of human DAT in ADHD and Bipolar disorder subjects adds translational significance to our efforts to decipher the presynaptic mechanisms that control DA release and inactivation. To date, these mechanisms have largely been studies through pharmacological and genetic manipulation of genes identified two decades or more ago. In the current application, we capitalize on a robust, forward genetic approach to identify and characterize novel presynaptic regulators of DA signaling using the powerful model system Caenorhabditis elegans. Over the past 15 years, the Blakely lab has developed skills in the C. elegans model with a focus on DAT and DA signaling, initiated by the identification of the C. elegans DAT gene (T23G5.5, dat-1). The present effort arises from our discovery of a simple DA and dat-1 dependent phenotype termed Swimming-Induced Paralysis (SWIP). Whereas wildtype animals thrash in water at ~1 Hz for up to 30 minutes, dat-1 (ok157) (DAT-deficient) animals paralyze in 3-5 minutes. This phenotype is dependent on DA synthesis, vesicular DA packaging, and DA release and is overcome by DAT activity. We request support to advance our screen to identify and characterize genes acting presynaptically to regulate DA release and reuptake, localize their mode of contribution to DA signaling, assess their impact on the actions of AMPH, and initiate an analysis of conserved vertebrate homologs. Together our efforts provide an opportunity to identify novel and conserved regulators of DA signaling that would be extremely difficult to elucidate in vertebrate models.

Public Health Relevance

DAT proteins are major presynaptic regulators of DA signaling and are targets of therapeutic and addictive psychostimulants. To identify novel presynaptic mechanisms that control DA release and reuptake, we implement a novel, forward genetic approach in the model system C. elegans. As all known regulators of DA signaling in mammals are conserved in C. elegans, our efforts have a high probability of yielding fundamental insights that underlie potential contributors to human, DA-dependent disorders as well as novel targets for medication development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH095044-02
Application #
8458053
Study Section
Neurotransporters, Receptors, and Calcium Signaling Study Section (NTRC)
Program Officer
Beckel-Mitchener, Andrea C
Project Start
2012-05-01
Project End
2017-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$374,077
Indirect Cost
$134,077
Name
Vanderbilt University Medical Center
Department
Neurosciences
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Refai, Osama; Blakely, Randy D (2018) Blockade and reversal of swimming-induced paralysis in C. elegans by the antipsychotic and D2-type dopamine receptor antagonist azaperone. Neurochem Int :
Gibson, Chelsea L; Codreanu, Simona G; Schrimpe-Rutledge, Alexandra C et al. (2018) Global untargeted serum metabolomic analyses nominate metabolic pathways responsive to loss of expression of the orphan metallo ?-lactamase, MBLAC1. Mol Omics 14:142-155
Robinson, Sarah B; Hardaway, J Andrew; Hardie, Shannon L et al. (2017) Sequence determinants of the Caenhorhabditis elegans dopamine transporter dictating in vivo axonal export and synaptic localization. Mol Cell Neurosci 78:41-51
Bermingham, Daniel P; Hardaway, J Andrew; Refai, Osama et al. (2017) The Atypical MAP Kinase SWIP-13/ERK8 Regulates Dopamine Transporters through a Rho-Dependent Mechanism. J Neurosci 37:9288-9304
Retzlaff, Cassandra L; Kussrow, Amanda; Schorkopf, Tim et al. (2017) Metallo-?-lactamase Domain-Containing Protein 1 (MBLAC1) Is a Specific, High-Affinity Target for the Glutamate Transporter Inducer Ceftriaxone. ACS Chem Neurosci 8:2132-2138
Wang, Haicui; Salter, Claire G; Refai, Osama et al. (2017) Choline transporter mutations in severe congenital myasthenic syndrome disrupt transporter localization. Brain 140:2838-2850
Bermingham, Daniel P; Hardaway, J Andrew; Snarrenberg, Chelsea L et al. (2016) Acute blockade of the Caenorhabditis elegans dopamine transporter DAT-1 by the mammalian norepinephrine transporter inhibitor nisoxetine reveals the influence of genetic modifications of dopamine signaling in vivo. Neurochem Int 98:122-8
Bermingham, Daniel P; Blakely, Randy D (2016) Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters. Pharmacol Rev 68:888-953
Hardaway, J Andrew; Sturgeon, Sarah M; Snarrenberg, Chelsea L et al. (2015) Glial Expression of the Caenorhabditis elegans Gene swip-10 Supports Glutamate Dependent Control of Extrasynaptic Dopamine Signaling. J Neurosci 35:9409-23
Rudnick, Gary; Krämer, Reinhard; Blakely, Randy D et al. (2014) The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflugers Arch 466:25-42

Showing the most recent 10 out of 14 publications